



(51) International Patent Classification:

A61K 31/4545 (2006.01) A61P 5/06 (2006.01)
C07D 401/04 (2006.01) A61P 5/10 (2006.01)

(21) International Application Number:

PCT/US2022/030721

(22) International Filing Date:

24 May 2022 (24.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/193,010 25 May 2021 (25.05.2021) US
63/274,409 01 November 2021 (01.11.2021) US

(71) Applicant: **CRINETICS PHARMACEUTICALS, INC.**
[US/US]; 10222 Barnes Canyon Road, Building #2, San
Diego, California 92121 (US).

(72) Inventors: **MADAN, Ajay**; 10222 Barnes Canyon Road,
Building #2, San Diego, California 92121 (US). **LUO, Sha
Rosa**; 10222 Barnes Canyon Road, Building #2, San Diego,
California 92121 (US). **KRASNER, Alan S.**; 10222 Barnes


Canyon Road, Building #2, San Diego, California 92121
(US).

(74) Agent: **ZUNIC, Valentin B.**; Wilson Sonsini, 650 Page
Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE



*Target=Mean trough concentration observed to suppress IGF-1
comparable to that of LA-SRLs in acromegaly patients

Figure 5

(57) Abstract: Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

29 December 2022 (29.12.2022)